I-PEX and Teramount Announce Collaboration on Detachable Fiber Interconnect for Silicon Photonics
I-PEX, a leader in the field of high-frequency and high-speed transmission connectors and Teramount Ltd, the leader in silicon photonics fiber packaging, today announced they are collaborating to advance silicon photonics optical detachable connectivity for data centers and for other high-speed datacom and telecom applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005012/en/
Detachable Photonic Plug for co-packaged optics serviceable fiber assembly (Photo: Teramount)
The ever-growing demand for high bandwidth, low power and low latency in networking and advanced computing applications has led to growing adoption of silicon photonics, and for a continuous need to connect more and more optical fibers to silicon chips. That connectivity needs to be reliable, reworkable, serviceable, and cost-effective, which creates a huge challenge. The collaboration between I-PEX and Teramount will provide a breakthrough solution of detachable fiber to chip connectivity based on Teramount’s self-aligning optics technology and I-PEX’s ultra-precision plug and holder systems.
“Detachable fiber connectivity to silicon photonic chips is a game changer for the industry. We have recently seen a growing number of customers who are interested in Teramount's Detachable Photonic Plug for their silicon photonics applications, as it enables a new era of serviceable and reliable fiber connectivity solutions” said Hesham Taha, chief executive officer. “I-PEX is a leader in the connector industry, and we are thrilled to partner with them to advance our technology to high volume industrial grade level manufacturing”
“We are very pleased to support the realization of Teramount's ground-breaking Detachable Photonic Plug concept with I-PEX's ultra-precise design and manufacturing capabilities” said Koichi Fujii, general manager, marketing of I-PEX. "We look forward to working with them to help penetrate silicon photonics solutions into data centers and other applications”
About I-PEX:
I-PEX is a unique and high-quality manufacturer of the world's most advanced connectors, sensors, complex molded parts, and other products based on the ultra-precision manufacturing process that has been perfected over the past 60 years. I-PEX, as an innovative product development and engineering solutions expert, is committed to exceeding the customer expectations around the world through global teamwork, aiming to be the company that our customers choose first. For more information, visit www.i-pex.com
About Teramount
Teramount changes the world of optical connectivity by offering a novel solution for connecting optics to silicon for data center, advanced computing, sensors and other datacom and telecom applications. Its innovative PhotonicPlug solution provides scalable connectivity of fibers to photonic chips and aligns photonics with standard semiconductor high-volume manufacturing and packaging capabilities. Teramount office is located in Jerusalem Israel. for more information, visit www.teramount.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005012/en/
Contact information
Teramount Contacts:
Hesham Taha
Chief Executive Officer
Teramount Ltd.
Tel: + 972 50 641 9792
E-mail: info@teramount.com
I-PEX Contacts:
Koichi Fujii
General Manager, Marketing
I-PEX Inc.
Tel : + 81 45 472 7111
URL: www.i-pex.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 13:57:00 CEST | Press release
TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)